Spruce Biosciences, Inc. (SPRB)
NASDAQ: SPRB · Real-Time Price · USD
159.37
-23.23 (-12.72%)
Oct 8, 2025, 3:55 PM EDT - Market open
Spruce Biosciences Revenue
Spruce Biosciences had revenue of $1.30M in the twelve months ending June 30, 2025, down -86.43% year-over-year. In the year 2024, Spruce Biosciences had annual revenue of $4.91M, down -51.32%.
Revenue (ttm)
$1.30M
Revenue Growth
-86.43%
P/S Ratio
80.17
Revenue / Employee
$61,857
Employees
21
Market Cap
89.73M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 4.91M | -5.18M | -51.32% |
Dec 31, 2023 | 10.09M | - | - |
Dec 31, 2022 | - | - | - |
Dec 31, 2021 | - | - | - |
Dec 31, 2020 | - | - | - |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
SPRB News
- 1 day ago - Spruce: BTD For TA-ERT For MPS IIIB Could Ignite BLA Submission With Added Bonuses (Rating Upgrade) - Seeking Alpha
- 1 day ago - This Biotech Stock Soared 1,400%. Investors Are Optimistic About Its Rare-Disease Drug. - Barrons
- 2 days ago - Spruce Biosciences Receives U.S. FDA Breakthrough Therapy Designation for Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) in Sanfilippo Syndrome Type B (MPS IIIB) - Business Wire
- 23 days ago - Spruce Biosciences Resumes Trading on the Nasdaq Capital Market - Business Wire